PULSE BIOSCIENCES, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
On August 6, 2026, Pulse Biosciences entered into an Equity Distribution Agreement with Mizuho Securities USA LLC allowing the company to sell up to $75,000,000 of common stock at-the-market via Mizuho as sales agent. Mizuho receives up to 3.0% commission on gross proceeds. The offering is registered under an existing Form S-3 (File No. 333-293596) effective February 27, 2026.
Why this rating
$75M ATM represents ~28% of company's $266M market cap—material capacity but execution-dependent. No immediate capital raised, no dilution yet, typical shelf financing flexibility.
Extracted items
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.